For ANGPTL4, although clinical studies targeting this hepatokine are not currently available, a recent study in mice, where the Angptl4 gene was specifically inhibited in the liver, highlighted its promising future therapeutic potential to improve metabolic homeostasis and prevent diet-induced obesity, without important adverse effects [95]. This evidence concerns the gene ANGPTL4 and obesity disorder.